Cargando…
Statins Neuromuscular Adverse Effects
Statins are drugs widely prescribed in high-risk patients for cerebrovascular or cardiovascular diseases and are, usually, safe and well tolerated. However, these drugs sometimes may cause neuromuscular side effects that represent about two-third of all adverse events. Muscle-related adverse events...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369175/ https://www.ncbi.nlm.nih.gov/pubmed/35955495 http://dx.doi.org/10.3390/ijms23158364 |
_version_ | 1784766378812637184 |
---|---|
author | Attardo, Silvia Musumeci, Olimpia Velardo, Daniele Toscano, Antonio |
author_facet | Attardo, Silvia Musumeci, Olimpia Velardo, Daniele Toscano, Antonio |
author_sort | Attardo, Silvia |
collection | PubMed |
description | Statins are drugs widely prescribed in high-risk patients for cerebrovascular or cardiovascular diseases and are, usually, safe and well tolerated. However, these drugs sometimes may cause neuromuscular side effects that represent about two-third of all adverse events. Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more rarely, rhabdomyolysis. Moreover, they may lead to peripheral neuropathy and induce or unmask a preexisting neuromuscular junction dysfunction. A clinical follow up of patients assuming statins could reveal early side effects that may cause neuromuscular damage and suggest how to better modulate their use. In fact, statin dechallenge or cessation, or the alternative use of other lipid-lowering agents, can avoid adverse events. This review summarizes the current knowledge on statin-associated neuromuscular adverse effects, diagnosis, and management. It is conceivable that the incidence of neuromuscular complications will increase because, nowadays, use of statins is even more diffused than in the past. On this purpose, it is expected that pharmacogenomic and environmental studies will help to timely predict neuromuscular complications due to statin exposure, leading to a more personalized therapeutic approach. |
format | Online Article Text |
id | pubmed-9369175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93691752022-08-12 Statins Neuromuscular Adverse Effects Attardo, Silvia Musumeci, Olimpia Velardo, Daniele Toscano, Antonio Int J Mol Sci Review Statins are drugs widely prescribed in high-risk patients for cerebrovascular or cardiovascular diseases and are, usually, safe and well tolerated. However, these drugs sometimes may cause neuromuscular side effects that represent about two-third of all adverse events. Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more rarely, rhabdomyolysis. Moreover, they may lead to peripheral neuropathy and induce or unmask a preexisting neuromuscular junction dysfunction. A clinical follow up of patients assuming statins could reveal early side effects that may cause neuromuscular damage and suggest how to better modulate their use. In fact, statin dechallenge or cessation, or the alternative use of other lipid-lowering agents, can avoid adverse events. This review summarizes the current knowledge on statin-associated neuromuscular adverse effects, diagnosis, and management. It is conceivable that the incidence of neuromuscular complications will increase because, nowadays, use of statins is even more diffused than in the past. On this purpose, it is expected that pharmacogenomic and environmental studies will help to timely predict neuromuscular complications due to statin exposure, leading to a more personalized therapeutic approach. MDPI 2022-07-28 /pmc/articles/PMC9369175/ /pubmed/35955495 http://dx.doi.org/10.3390/ijms23158364 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Attardo, Silvia Musumeci, Olimpia Velardo, Daniele Toscano, Antonio Statins Neuromuscular Adverse Effects |
title | Statins Neuromuscular Adverse Effects |
title_full | Statins Neuromuscular Adverse Effects |
title_fullStr | Statins Neuromuscular Adverse Effects |
title_full_unstemmed | Statins Neuromuscular Adverse Effects |
title_short | Statins Neuromuscular Adverse Effects |
title_sort | statins neuromuscular adverse effects |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369175/ https://www.ncbi.nlm.nih.gov/pubmed/35955495 http://dx.doi.org/10.3390/ijms23158364 |
work_keys_str_mv | AT attardosilvia statinsneuromuscularadverseeffects AT musumeciolimpia statinsneuromuscularadverseeffects AT velardodaniele statinsneuromuscularadverseeffects AT toscanoantonio statinsneuromuscularadverseeffects |